痛风治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

痛风治疗市场按药物类别、应用(急性痛风和慢性痛风)和地理划分。

市场快照

Gout Therapeutics Market_1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 15.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在预测期内,痛风治疗市场预计将以 15.5% 的复合年增长率增长。推动市场增长的主要因素是生物制剂的日益普及和再生药物研发的增加,成像方式的技术进步提高了对痛风的了解,以及由于饮酒量增加而导致痛风患病率上升。

例如,根据抗击慢性病伙伴关系(PFCD)的调查报告,在美国,痛风的患病率从 2000 年的 0.78% 上升到 2015 年的 1.51%。此外,2017 年的患病率为 1489.73(每 100,000 人)。

因此,痛风患病率的上升以及考虑到饮酒与痛风之间的关联,可以预期,在预测期内,增加饮酒将成为痛风治疗市场增长的驱动力。然而,药物的不良反应等因素可能会抑制市场增长。

报告范围

根据报告的范围,痛风是一种炎症性关节炎,发生在一些血液中尿酸水平高的人身上。酸会在关节中形成针状晶体,并引起突然的、严重的疼痛、压痛、发红、发热和肿胀。痛风治疗市场按药物类别、应用和地域划分。

By Drug Class
Antihyperuricemic Agents (Urate-Lowering Drugs)
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Other Drug Classes
By Application
Acute Gout
Chronic Gout
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

在痛风治疗市场的预测期内,抗高尿酸药物(降尿酸药物)细分市场预计将以高复合年增长率增长

痛风是最常见的炎症性关节炎,其特征是疼痛和致残的急性发作。它是由高尿酸血症和关节内和关节周围的尿酸盐结晶沉积引起的。长期未经治疗的高尿酸血症可导致慢性关节炎、关节损伤、痛风石形成和尿酸盐肾病。当谈到痛风时,降尿酸剂是最优选的治疗形式。该领域最常用的一些药物是黄嘌呤氧化酶抑制剂(别嘌醇和非布司他)、尿酸排泄药物(苯溴马隆、丙磺舒和磺吡酮)和尿酸酶(聚乙二醇化酶和拉布立克酶)。

此外,根据澳大利亚统计局和 2017-2018 年国家健康调查,估计有 187,000 名澳大利亚人(占人口的 0.8%)患有痛风。痛风在男性中比女性更常见,几乎十分之九(87%)的痛风患者是男性。因此,考虑到上述所有因素,预计该细分市场将在不久的将来出现增长。

Gout key trend 1.png

亚太地区有望成为痛风治疗市场增长最快的地区

预计亚太国家将见证该市场在预测期内的最快增长,其中包括印度、中国、韩国和其他南亚国家等几个经济增长较高的国家。患者群体多样化、主要参与者增加对本地制造商和连锁医院的投资等因素。据澳大利亚健康与福利研究所估计,2015-2016 年,痛风给澳大利亚卫生系统造成的损失估计为 1.765 亿美元,占肌肉骨骼疾病支出的 1.4% 和疾病总支出的 0.2%。此外,生活方式因素,例如吸烟率和饮酒率的增加以及压力过大的生活方式,可能会在此期间增加痛风的发病率。

Gout Therapeutics Market2

竞争格局

痛风治疗市场是分散竞争的,由几个主要参与者组成。就市场份额而言,目前很少有主要参与者主导市场。随着全球病例的日益流行,预计未来几年也将很少有其他公司进入市场。市场上的一些主要参与者包括 Lannett Company、Horizo​​n Therapeutics plc、GlaxoSmithKline PLC、Mylan 和 Takeda Pharmaceutical Company Ltd 等。

主要玩家

  1. Takeda Pharmaceutical Company Ltd

  2. Mylan NV

  3. GlaxoSmithKline Plc

  4. Lannett Company, Inc

  5. Horizon Therapeutics plc

Gout landscape.png

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Adoption of Biologics and Increasing R&D on Regenerative Medicines

      2. 4.2.2 Rising Prevalence of Gout with Increasing Alcohol Consumption

      3. 4.2.3 Technological Advancements in Imaging Modalities Improved Understanding of Gout

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Gout Therapeutic Drugs

      2. 4.3.2 High Indirect Costs of Gout Therapeutics

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Antihyperuricemic Agents (Urate-Lowering Drugs)

      2. 5.1.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)

      3. 5.1.3 Corticosteroids

      4. 5.1.4 Colchicine

      5. 5.1.5 Other Drug Classes

    2. 5.2 By Application

      1. 5.2.1 Acute Gout

      2. 5.2.2 Chronic Gout

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Lannett Company, Inc

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 GlaxoSmithKline PLC

      4. 6.1.4 Horizon Therapeutics plc

      5. 6.1.5 Mylan NV

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Regeneron Pharmaceuticals

      8. 6.1.8 Romeg Therapeutics, LLC.

      9. 6.1.9 Takeda Pharmaceutical Company Ltd

      10. 6.1.10 Teijin Pharma Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Gout Therapeutics Market market is studied from 2018 - 2026.

The Gout Therapeutics Market is growing at a CAGR of 15.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Takeda Pharmaceutical Company Ltd, Mylan NV, GlaxoSmithKline Plc, Lannett Company, Inc, Horizon Therapeutics plc are the major companies operating in Gout Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!